AlloSource® Showcases Innovative ViaTrue® Cryopreservation Research at ICRS World Congress
AlloSource® Showcases Innovative ViaTrue® Cryopreservation Research at ICRS World Congress
AlloSource®, a notable leader in the life sciences field, recently announced that it is presenting significant research on its proprietary ViaTrue® Cryopreservation Process during the 18th International Cartilage Regeneration & Joint Preservation Society (ICRS) World Congress. This research underscores the positive clinical and scientific outcomes associated with two of AlloSource's cartilage allografts, contributing to advancements in joint health and recovery.
The ViaTrue® Cryopreservation Process
The ViaTrue technology represents a cutting-edge method of cryopreservation, which involves carefully freezing fresh cartilage within 72 hours post-donor death. This timeframe is critical as it ensures that the chondrocytes—the cells responsible for cartilage health—remain highly viable. Under this process, cartilage products can be preserved for up to two years, maintaining excellent cellular integrity. This innovative approach not only facilitates better storage but also significantly enhances the flexibility available to surgeons in managing allografts for their patients.
Research Highlights from ICRS
One of the standout studies presented is titled "5-Year Outcomes After Cryopreserved Osteochondral Allograft: Interim Analysis of IKDC and KOOS Scores in Knee Cartilage Repair". This research evaluates the outcomes of patients who underwent treatment with ProChondrix® CR Osteochondral Allograft for specific knee cartilage lesions. The initial findings demonstrate significant enhancements in patient-reported outcome measures—up to 60 months post-treatment—indicating that ProChondrix® CR may serve as a sustainable solution for improving the quality of life and joint functionality in individuals suffering from focal cartilage damage. Given the ongoing nature of this study, additional outcomes will emerge as more patients complete the 60-month follow-up period.
Another pivotal poster presented by Colorado State University in Fort Collins explored the comparative analysis of fresh versus cryopreserved osteochondral allografts. The study, titled “Cryopreservation Vs Fresh Osteochondral Allografts: Is There a Difference?”, assessed both histologic and biomechanical properties across the two graft types, revealing minimal differences between them. These findings position cryopreservation as a promising alternative to traditional methods of grafting, potentially addressing logistical challenges and enhancing accessibility for patients requiring joint transplants.
Expert Insights
AlloSource’s Senior Director of Product Development, Carolyn Rorick, commented on the significance of the ViaTrue process, stating, “Cryopreserving allografts with ViaTrue helps to alleviate inventory management challenges and provides surgeons with more flexibility for their patients.” She emphasized the ongoing evaluations are crucial for validating the influence that cryopreserved cartilage can have on the healing process.
Dr. Laurie Goodrich, Director of the Orthopaedic Research Center at Colorado State University, also highlighted the potential of these findings. She remarked, “There is still research to do in the body to show that cryopreserved osteochondral allografts are as good as fresh allografts, but this work is the first step towards proving that cryopreserved grafts can be a viable option for the millions of patients that need them.”
Conclusion
The ICRS World Congress serves as a vital platform for scientists, researchers, clinicians, and industry experts to collaborate and share insights on cartilage research. As AlloSource showcases the impressive results of the ViaTrue® Cryopreservation Process, it reinforces its commitment to improving patient outcomes and revolutionizing the use of human tissue in medical treatments. For those interested in further details, AlloSource presents its findings through their E-Poster online and invites attendees to visit their booth #31 at the congress.
With its profound dedication to advancing the field of cartilage regeneration and joint preservation, AlloSource continues to be at the forefront of transforming patient care through innovation and scientific research.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.